Uniqure NV（QURE）資訊與事件

$48.720

-0.823 (-1.69%)收盤時

QURE 資訊

5.008-25CNBC

FDA to Create New Deputy Commissioner Roles Focused on AI and Drug Regulation

2.008-08NASDAQ.COM

uniQure (QURE) Q2 2026 Earnings Call Transcript

8.508-02NASDAQ.COM

Five Biotech Stocks Investors Should Watch

6.007-30CNBC

Wall Street's Latest Ratings Overview

9.507-29seekingalpha

uniQure Q2 2026 Earnings Call Insights

8.507-29Globenewswire

uniQure Advances AMT-130 for Huntington's Disease Treatment

8.506-24seekingalpha

FDA's Regulatory Reversal Boosts Biotech Sector

8.506-24seekingalpha

uniQure Prices Public Offering at $225 Million

8.506-24NASDAQ.COM

uniQure N.V. Upsizes Public Offering to $225 Million

8.506-24Newsfilter

uniQure Prices Public Offering at $45.50 per Share, Raising $225 Million

查看更多資訊

QURE 事件

7/29 07:30

uniQure Reports Q2 Revenue of $5.84M, Exceeds Expectations

Reports Q2 revenue $5.84M, consensus $4.71M. "This has been a defining quarter - not just for uniQure, but for the Huntington's disease community," said Matthew Kapusta, chief executive officer at uniQure. "Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter - a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease. With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it."

6/23 22:00

Deal Size Increased to $225M

The deal size was increased to $225M from $150M and priced below the last closing price of $49.04 per share. Leerink and Stifel are acting as joint book running managers for the offering.

6/23 10:30

uniQure Stock Rises 7.6% to $47.74

uniQure is up 7.6%, or $3.35 to $47.74.

6/22 16:30

Leerink Partners and Stifel Act as Bookrunning Managers for Proposed Offering

Leerink Partners and Stifel are acting as bookrunning managers for the proposed offering.

6/22 07:00

Regenxbio CEO: FDA Agrees to Reconsider Gene Therapy Application

Regenxbio (RGNX) Chief Executive Curran Simpson said the Food and Drug Administration has agreed to reverse its rejection of an experimental gene therapy for a rare and fatal brain disease and that Regenxbio plans to refile its application seeking approval of its Navsunli gene therapy in the third quarter, after it holds a formal meeting to resolve disputes with the FDA that is expected in July, according to The Wall Street Journal's Xavier Martinez. Another biotech, Replimune (REPL), reached an agreement with the FDA last month to resubmit its twice-rejected melanoma therapy and earlier this month uniQure (QURE) said the FDA had reversed course on its Huntington's disease gene therapy.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。